首頁(yè) > 促銷(xiāo)活動(dòng) > 優(yōu)勢(shì)產(chǎn)品 英國(guó)BBI Solutions成立于1986年，是體外診斷試劑領(lǐng)域?qū)I(yè)制造商，為生命科學(xué)行業(yè)和體外診斷行業(yè)提供診斷試劑原料、標(biāo)準(zhǔn)品及技術(shù)服務(wù)，現(xiàn)已從一家小型專(zhuān)業(yè)公司成長(zhǎng)為業(yè)務(wù)生產(chǎn)基地橫跨三個(gè)國(guó)家的大型企業(yè)。
BBI Solutions主要經(jīng)營(yíng)產(chǎn)品包括人源抗原、抗體、血清、血漿、臨床化學(xué)酶和黃金納米顆粒。
BBI Solutions人源蛋白
BBI Solutions人源蛋白是從人類(lèi)血清或組織中純化所得，符合倫理法規(guī)要求；重組蛋白使用大腸桿菌和畢赤酵母表達(dá)系統(tǒng)，在專(zhuān)業(yè)的實(shí)驗(yàn)室中進(jìn)行生產(chǎn)；去血清產(chǎn)品，可顯著消除基質(zhì)效應(yīng)，提高生物標(biāo)志物的檢測(cè)效果，并產(chǎn)生可重復(fù)的標(biāo)準(zhǔn)曲線。
重組載脂蛋白 Neutrophil Gelatinase Associated Lipocallin (NGAL recombinant) P722-1
NGAL is a new early marker for acute kidney injury. Levels rise rapidly after renal injury and have been used in a variety of clinical situations including intensive care, emergency medicine, renal transplantation and procedures involving the use of i.v.contrast media and other nephrotoxic agents. Studies have indicated that this marker has the greatest potential for the prediction and monitoring of acute renal injury following cardiac surgery. This potential has now been expanded upon, with development and commercialisation of highly specific ELISA testing kits.
產(chǎn)品詳情：https://www.bbisolutions.com/cn/product/lipocalin-ngal-recombinant
希凱生物是英國(guó)BBI Solutions授權(quán)代理商，更多產(chǎn)品信息，歡迎直接與我們聯(lián)系~
北京 010-62220605 | 上海 021-66520678 | 廣州 15712937545
